Similarly, treatment with temozolomide (TMZ) induces the overexpression of activating transcription factor 4 (ATF4), which promotes DNA damage-inducible transcript 4 (DDIT4)/GLUT3 signaling and enhances resistance to TMZ in GBM (Ho et al. 2020). This evidence concerns the gene DDIT4 and glioblastoma.